|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||-1.94|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
With the addition of GenVec's AdenoVerse™ technology and accomplished team, Intrexon intends to create the next generation of adenoviral (AdV) delivery with significantly higher payload capacity that exceeds 30kb, as compared to current viral delivery methods ranging from 4.5kb – 9kb, through a scalable manufacturing platform utilizing helper-dependent adenovirus. Additionally Intrexon's RheoSwitch Therapeutic System® platform combined with GenVec's AdV-based technology is projected to accelerate its ability to develop cutting-edge gene therapies that regulate in vivo expression of one or several therapeutic effectors. GenVec's selection of vector origins and serotypes as well as know-how in specifying cellular and tissue targets is expected to expedite the design and production of vectors that complement Intrexon's multigene programming and keen focus on safety with limited off-target effect.
Categories: Yahoo FinanceGet free summary analysis GenVec, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of GenVec, Inc. – Emergent BioSolutions Inc., Pfizer Inc., Novavax, Inc., Novartis AG Sponsored ADR, Merck & Co., Inc., Astrazeneca PLC Sponsored ADR and Johnson & Johnson (EBS-US, PFE-US, NVAX-US, ... Read more (Read more...)
NEW YORK, April 23, 2017 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities class action firm headquartered at the Empire State Building ...